<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471834</url>
  </required_header>
  <id_info>
    <org_study_id>360016</org_study_id>
    <nct_id>NCT01471834</nct_id>
  </id_info>
  <brief_title>Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension</brief_title>
  <official_title>Neo Non-Randomized Hypertension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834)
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Neo Non-Randomized Hypertension Study is a non-randomized, open-label, verification study
      in participants diagnosed with drug resistant hypertension, defined as medical treatment
      failure for hypertension defined as office cuff systolic blood pressure (SBP) ≥ 140 mmHg
      despite being prescribed to at least three antihypertensive medications, including a
      diuretic, in accordance with the AHA guidelines.

      Participants should remain on their prescribed anti-hypertensive medications and same dosing
      schedule for the duration of the study unless investigators determine medically necessary
      changes are needed. Additionally, every effort should be made to maintain adequate rate
      control for subjects with atrial fibrillation throughout the duration of the study.

      All (Canadian) participants are now in long term follow-up and are required to have at least
      one annual visit.

      Parameters assessed during long-term follow-up visits:

        -  Physical Assessment

        -  Office Cuff Blood Pressure

        -  Subject Medications

        -  Serious adverse events
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To access long-term adverse events in participants implanted with the BAROSTIM NEO System.</measure>
    <time_frame>For the duration of the study, up to 10 years.</time_frame>
    <description>Ascertain the type, frequency, severity and timing of long-term adverse events in participants implanted with the device, while providing a viable treatment option to participants currently implanted with CVRx's BAROSTIM NEO System.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Device and Medical Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be implanted with the BAROSTIM NEO System and will continue to receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BAROSTIM NEO System</intervention_name>
    <arm_group_label>Device and Medical Management</arm_group_label>
    <other_name>XR-1 System</other_name>
    <other_name>Neo System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Management</intervention_name>
    <arm_group_label>Device and Medical Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Actively participating in the Neo Non-Randomized Hypertension Study.

          -  Have signed a revised approved informed consent form for continued participation in
             this study.

        Exclusion Criteria:

          -  Treating physician decision that the subject should not continue with therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hermann Haller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta - Edmonton</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T2P 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London-Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologn</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goettingen-Georg August University</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinkum St. George Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <zip>HX6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

